

Pathology Blocks/Slides for consultation: Patient Communication

 Released

 Not seen

Results

Pathology Blocks/Slides for consultation (Order 90043548)

Pathology Blocks/Slides for consultation: S24-09221

Order: 90043548

Status: Edited Result - FINAL Visible to patient: Yes (not seen)

Next apt: 11/09/2024 at 08:00 AM in Oncology (ACC Infusion Recliner 13)

Component

Case Report

SURGICAL PATHOLOGY

Case: S24-09221

Authorizing Provider: Hazem Ihssan Assi, MD
19/08/2024 12:49

Collected:

Ordering Location:
19/08/2024 15:02

Pathology and Laboratory Received:

Medicine - Ambulatory

Service

Pathologist: Nawwaf Mohammad Hicham

Jurdi, MD

Specimens: 1) - Kidney Non-Medical, Left, 24-04453

2) - Lung, 24-04454

3) - Lymph node, 24-04452

Addendum

ALK (D5F3 - Ventana): Negative.
ROS1(D4D6): Negative.

Addendum electronically signed by Nawwaf Mohammad Hicham Jurdi, MD on 28/08/2024 at 08:40

Diagnosis

**1. RIGHT KIDNEY, CORE BIOPSY, RECEIVED BLOCK "B24-4453/1A":
- INVOLVED BY POORLY DIFFERENTIATED ADENOCARCINOMA.**

**2. LEFT LUNG, CORE BIOPSY, RECEIVED BLOCK "B24-4454/1A":
- INVASIVE MODERATELY TO POORLY DIFFERENTIATED ADENOCARCINOMA.
- SEE COMMENT.**

**3. LEFT SUPRACLAVICULAR LYMPH NODE, CORE BIOPSY, RECEIVED BLOCK "B24-4452/1A":
- METASTATIC POORLY DIFFERENTIATED ADENOCARCINOMA.**

Electronically signed by Nawwaf Mohammad Hicham Jurdi, MD on 21/08/2024 at 21:35

Comment

The tumors in all three biopsies are morphologically similar and most likely represent the same primary. The immunoprofile is non-specific. A variety of tumors including neuroendocrine tumors, squamous cell carcinoma, mullerian tumors, renal cell carcinoma and mammary carcinoma, are less likely on immunohistochemical grounds. The findings are most consistent with a poorly differentiated pulmonary adenocarcinoma metastatic to supraclavicular lymph node and kidney. Correlation with clinical and

radiological data is needed.

Immunohistochemis

try

Immunostains are performed on formalin-fixed paraffin-embedded sections of block 2A using a polymer detection system. All controls show appropriate reactivity. The tumor cells are positive for CK7, TTF-1 (focal), Napsin A (focal) and CDX-2 (focal). They are negative for CK20, P40, GATA-3, synaptophysin and PAX-8. Alk and ROS-1 will follow.

PD-L1 (22C3 DAKO): TPS = 0 and CPS = 0.

Gross Description

Received is one block labeled "B24-4453/1A", from Geitaoui Hospital with a corresponding pathology report dated 22/07/2024 and signed by Dr. Claude Sader Ghorra.

Received is one block labeled "B24-4454/1A", from Geitaoui Hospital with a corresponding pathology report dated 22/07/2024 and signed by Dr. Claude Sader Ghorra.

Received is one block labeled "B24-4452/1A", from Geitaoui Hospital with a corresponding pathology report dated 22/07/2024 and signed by Dr. Claude Sader Ghorra.

Specimen Collected: 19/08/24 12:49

Last Resulted: 28/08/24 08:40

-  [Order Details](#)
-  [View Encounter](#)
-  [Lab and Collection Details](#)
-  [Routing](#)
-  [Result History](#)

Scans on Order 90043548

Document type: Lab Result Document - Media type: Document Date: 28/08/2024 08:40 AM

Result Care Coordination

 Patient Communication

 Released  Not seen

PACS Images & Report

(Link Unavailable) Show images for Pathology Blocks/Slides for consultation

All Reviewers List

Houry Ghougas Hagop Kazarian on 28/08/2024 11:12

Lab Information

Lab
 AUBMC PATHOLOGY AND LABORATORY MEDICINE
 Responsible Users
 Nawwaf Mohammad Hicham Jurdi, MD Staff Pathologist

Additional Information

Specimen ID	Bill Type	Client ID			
S24-09221					
Specimen Date Taken	Specimen Time Taken	Specimen Received Date	Specimen Received Time	Result Date	Result Time
19 Aug 2024	12:49 PM	19 Aug 2024	3:02 PM	28 Aug 2024	8:40 AM

Routing History

Priority	Sent On	From	To	Message Type
	21/08/2024 09:35 PM	Lab, Background User	Hazem Ihssan Assi, MD	Results

LDT Disclaimers:

POC, COVID-19/Flu A&B Rapid Ag Detection:

A negative test result does not eliminate the possibility of SARS-COV-2 and influenza A&B infection and should be confirmed by molecular testing if necessary for patient management.

POC, COVID-19 Rapid Ag Detection:

Any negative Ag test should be confirmed with PCR.

POC, Glucose:

The Glucose testing using Accu-check Performa was developed and its performance characteristics determined by the Pathology and Laboratory Medicine Department at AUBMC. It has not been cleared or approved by the FDA. The laboratory is CAP accredited and qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

POC, Tramadol:

"Instant-View "Tramadol Cassette test was developed and its performance characteristics determined by the Pathology and Laboratory Medicine Department at AUBMC. It has not been cleared or approved by the FDA. The laboratory is CAP accredited and qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

General Note for all POC Drug of Abuse tests and POC Tramadol

Drugs of abuse screening: AUBMC does not assume any responsibility or liability whatsoever with respect to the genuineness or condition the urine specimen from whom it is reported to be taken.

It is also being clearly agreed and understood that the immunoassay test for drug abuse is simply carried out as a screening test for clinical purposes and any results thereof need to be further confirmed by other analytical procedures; it is further agreed and understood that AUBMC assumes no responsibility or liability for the consequences, if any, resulting from the use of the test or the interpretation of the findings thereof and that AUBMC is and shall remain independent of the purpose for which the performance of the test is requested or the use for which the test is intended.